BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Welichem Biotech readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Welichem Biotech's drugs run\, fr
 om ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07265479-1783@assetmemo.bio
DTSTAMP:20261121T010209Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Tapinarof: Phase 3 readout est. (NCT07265479)
DESCRIPTION:Tapinarof\, phase 3\, Atopic Dermatitis.\nStudy: A Study to Inv
 estigate Safety and Efficacy of Tapinarof Cream\, 1% in Participants Ages 
 3 Months to < 24 Months With Atopic Dermatitis\nEstimated primary completi
 on: August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tapi
 narof#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07265479
URL:https://assetmemo.bio/drug/tapinarof#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
